Table 1 Baseline characteristics of the study population (n = 366). Comorbidities were collected only for the patients with complete medical histories (n = 274)
| Â | n (%) |
|---|---|
All (n = 366) | |
Age (median, range) | 64 (26-96) |
Insurance | |
 private | 16 (4.4) |
 statutory | 350 (95.6) |
Sex | |
 female | 110 (30.1) |
 male | 256 (69.9) |
Smoking | |
 no | 128 (35.0) |
 yes | 150 (41.0) |
 unknown | 88 (24.0) |
Localisation | |
 nasopharynx | 15 (4.1) |
 oropharynx | 138 (37.7) |
 hypopharynx | 42 (11.5) |
 larynx | 51 (13.9) |
 oral cavity | 51 (13.9) |
 salivary glands | 19 (5.2) |
 paranasal sinus | 17 (4.6) |
 others | 33 (9.0) |
Histology | |
 squamous cell carcinoma | 279 (76.2) |
 adenocarcinoma | 35 (9.6) |
 undifferentiated | 24 (6.6) |
 others | 28 (7.7) |
Grading | |
 1 | 31 (8.5) |
 2 | 185 (50.5) |
 3 | 110 (30.1) |
 4 | 24 (6.6) |
 unknown | 16 (4.4) |
Radiotherapy | |
 definitive | 216 (59.0) |
 adjuvant | 150 (41.0) |
 re-radiation | 18 (4.9) |
Radiotherapy technique (n = 274) | |
 3D | 24 (8.8) |
 IMRT | 250 (91.2) |
Concomitant chemotherapy | |
 yes | 173 (47.3) |
 no | 180 (49.2) |
 unknown | 13 (3.6) |
Inpatient, days (median, range) | 23 (1-55) |
 yes | 191 (52.2) |
 no | 171 (46.7) |
 unknown | 4 (1.1) |
Secondary malignancy | |
 yes | 36 (9.8) |
Charlson score | |
 (median, range) at the baseline | 4 (2-13) |
Comorbidity (n = 274) | |
 Neurological comorbidity | 24 (8.8) |
 Nephrological comorbidity | 14 (5.1) |
 Cardiovascular comorbidity | 109 (39.8) |
 Diabetes mellitus | 27 (9.9) |
 COPD | 20 (5.5) |
 One comorbidity | 78 (28.5) |
 Two comorbidities | 29 (10.6) |
 Three comorbidities | 9 (3.3) |
 Four comorbidities | 5 (1.8) |
 Five comorbidities | 1 (0.4) |